See more : Hi Sun Technology (China) Limited (HISNF) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroSense Therapeutics Ltd. (NRSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroSense Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Pulau Subur Tbk (PTPS.JK) Income Statement Analysis – Financial Results
- VERBIO Vereinigte BioEnergie AG (0NLY.L) Income Statement Analysis – Financial Results
- Orpea SA (ORRRY) Income Statement Analysis – Financial Results
- Globe Union Industrial Corp. (9934.TW) Income Statement Analysis – Financial Results
- Haidilao International Holding Ltd. (6862.HK) Income Statement Analysis – Financial Results
NeuroSense Therapeutics Ltd. (NRSN)
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.00K | 89.00K | 3.00K | 3.00K | 0.00 |
| Gross Profit | -97.00K | -89.00K | -3.00K | -3.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.27M | 6.42M | 3.08M | 2.50M | 898.00K |
| General & Administrative | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Cost & Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Interest Income | 178.00K | 91.00K | 0.00 | 61.00K | 18.00K |
| Interest Expense | 550.00K | 15.00K | 1.15M | 1.00K | 5.00K |
| Depreciation & Amortization | 97.00K | 89.00K | 3.00K | 3.00K | 1.24M |
| EBITDA | -10.63M | -13.38M | -2.88M | -2.83M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.05M | -13.55M | -5.59M | -2.89M | -1.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 769.00K | 1.21M | 1.55M | 60.00K | 13.00K |
| Income Before Tax | -11.28M | -12.34M | -4.04M | -2.83M | -1.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -1.55M | 1.00K | 5.00K |
| Net Income | -10.11M | -11.20M | -2.50M | -2.83M | -1.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| EPS Diluted | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| Weighted Avg Shares Out | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
| Weighted Avg Shares Out (Dil) | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
Why Is NeuroSense (NRSN) Stock Up 35% Today?
NRSN stock is on the move in the wake of encouraging clinical results for a novel drug combination to treat Alzheimer's disease. The post Why Is NeuroSense (NRSN) Stock Up 35% Today?
3 Penny Stocks To Watch While The Stock Market Is Down
Penny stocks for your watch list with the stock market down today. The post 3 Penny Stocks To Watch While The Stock Market Is Down appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker Study
NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD). Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating.
3 Penny Stocks To Watch After GDP Report
Penny stocks to buy or avoid right now? You decide after seeing the latest updates from 3 companies.
Best Penny Stocks to Buy as June Ends? 3 to Watch
Check these three penny stocks out right now The post Best Penny Stocks to Buy as June Ends? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NeuroSense Therapeutics (NRSN) Stock Pops on Positive ALS Study Results
NRSN stock is getting plenty of attention today and a bid to the tune of more than 70% in the wake of positive clinical results. The post NeuroSense Therapeutics (NRSN) Stock Pops on Positive ALS Study Results appeared first on...
NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022
Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS" Phase IIb ALS study for NeuroSense's combination therapy PrimeC expected to commence Q2 2022 CAMBRIDGE, Mass. , May...
Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
12 Stocks Halted On A Circuit Breaker This Week
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.
Neurosense multiplies investor value 3X. Buy the penny stock and wait
Neurosense Therapeutics Ltd (NASDAQ:NRSN) tripled market value in a day. This was after announcing approval by the US Food and Drugs Authority to advance research on a drug for Amyotrophic Lateral Sclerosis.
Source: https://incomestatements.info
Category: Stock Reports